Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

Core Points - Oncolytics Biotech Inc. held its Annual General Meeting (AGM) on May 15, 2024, with 41.34% of the issued and outstanding common shares represented [1] - All eight nominees proposed by the Corporation were elected as Directors, with voting percentages for each nominee ranging from 70.97% to 84.78% [2] - Shareholders approved all other resolutions, including fixing the number of directors at eight and appointing auditors for the upcoming year [2] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent [4] - Pelareorep has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer, inducing anti-cancer immune responses [4] - The company is conducting combination clinical trials with pelareorep in various malignancies and is advancing towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [5]